The EIS method is based on the use of electronic impedance measurements to evaluate alterations in the skin. The method developed quickly and was shown to work well on various human tissues. When SciBase was founded in 1998, Ollmar and his team were mainly studying various skin reactions such as allergies and had not yet begun to focus on cancer. Below are some of the discoveries that paved the way for Nevisense:
• 2021 – Nevisense shows potential for assessment of skin Barrier and Atopic dermatitis
• 2021 – Nevisense is now also indicated for Keratinocyte cancers based on data from several clinical studies .
• 2018 – Launch of Nevisense 3.0. Update of the Nevisense EIS classifier algorithm. Improved accuracy in both sensitivity and specificity.
• 2017 – Scibase receives US PMA approval for Nevisense from FDA
• 2017 – A study published in British Journal of Dermatology showing reduced need for SDDI (short term digital dermoscopy imaging) when adding Nevisense at baseline examination.
• 2016 – Scibase insources the production of electrodes from Ginolis.
• 2016 – Launch Nevisense View – added functionality to collect and store clinical images in Nevisense.
• 2015 – SciBase listed on Nasdaq First North.
• 2014 – SciBase pivotal study results published in British Journal of Dermatology.
• 2012 – Method clinically verified in the largest prospective clinical study ever conducted in melanoma detection.
• 2010 – Algorithm development completed for the final classifier for the Nevisense system.
• 2008 – Product development of the Nevisense device completed.
• 2004 – Proof of Principle for the use of EIS for the detection of Malignant Melanoma was achieved with the use of a micro-invasive electrode.
• 2003 – A pilot study showed that non-melanoma-skin cancer could be distinguished from benign lesions using a non-invasive electrode without micro-spikes.
• 1998 – SciBase was founded and it soon became apparent that it was possible to measure skin lesions as well as mucous membranes. The method proved able to distinguish various types of reactions and specific irritations in the skin.
• 1993 – The method was refined enabling measurement of variations at a controlled and variable depth from only one side.
• 1989 – Using electrical impedance, Ollmar’s research team discovered various degrees of irritation in the mucous membranes of the mouth. The measurement instrument was used on both the inside and outside of the mouth.
• 1980s – Associate Professor Stig Ollmar and his research colleagues began establishing the foundations of what today is the SciBase method based on EIS (Electronic Impedance Spectroscopy).
The evolution of EIS
SciBase was founded in 1998 by Associate Professor Stig Ollmar at Karolinska Institutet Stockholm. Beginning as early as the 1980s, Stig Ollmar and his research colleagues established the foundation of what today is the SciBase method based on Electrical Impedance Spectroscopy (EIS).
The idea of developing a probe to assess skin cancer was first conceptualized when the researchers behind SciBase realized that it was possible to measure the different electrical properties of healthy skin compared to irritated skin. These early tests looked at the effects of common irritants, such as soap, and their effects on the skin. After adjusting and refining the algorithm that interprets the measurement data, it became clear that it was also possible to discover the different characteristics typical of cancerous vs. non-cancerous cells. This discovery led Associate Professor Ollmar, the inventor of the EIS method used by SciBase, to develop a sensitive probe with microscopic pins.
The technology platform has been tested for several years on experimental reactions of healthy volunteers, as well as on patients with various diseases of the skin or the oral mucosa. The technology has been found capable of detecting various types of tissue alterations.
For more information, please see the list of scientific publications.